Targeting angiogenesis in cancer: clinical development of bevacizumab
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,General Medicine
Link
http://www.nature.com/articles/ncponc0026.pdf
Reference16 articles.
1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182–1186
2. Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2: 795–803
3. Ferrara N et al. (2003) The biology of VEGF and its receptors. Nat Med 9: 669–676
4. Ferrara N et al. (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391–400
5. Gordon MS et al. (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19: 843–850
Cited by 80 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Systematic Reversal of Drug Resistance in Cancer;Targets;2024-09-13
2. Integrating Vascular Phenotypic and Proteomic Analysis in an Open Microfluidic Platform;ACS Nano;2024-08-29
3. Decoding the Role of O-GlcNAcylation in Hepatocellular Carcinoma;Biomolecules;2024-07-25
4. VEGF as a Key Actor in Recurrent Respiratory Papillomatosis: A Narrative Review;Current Issues in Molecular Biology;2024-07-01
5. Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer;PLOS ONE;2024-06-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3